Vijay Kumar Gaba

 RBI monetary policy statement highlights

·         Status quo on policy rates and monetary policy stance (withdrawal of accommodation).

·         The MPC resolved to continue keeping a close vigil on the evolving inflation and growth outlook. It will take further monetary actions promptly and appropriately as required to keep inflation expectations firmly anchored and to bring down inflation to the target. The MPC also decided to remain focused on withdrawal of accommodation to ensure that inflation progressively aligns with the target, while supporting growth.

·         Domestic economic activity remains resilient in Q1:2023-24 as reflected in high frequency indicators. Purchasing managers’ indices (PMI) for manufacturing and services indicated sustained expansion, with the manufacturing PMI at a 31-month high in May and services PMI at a 13-year high in April-May. In the services sector, domestic air passenger traffic, e-way bills, toll collections and diesel consumption exhibited buoyancy in April-May, while railway freight and port traffic registered modest growth.

·         On the demand side, urban spending remains robust as reflected in indicators such as passenger vehicle sales and domestic air passenger traffic which recorded double digit growth in April. Rural demand is gradually improving though unevenly.

·         Money supply (M3) expanded by 10.1 per cent y-o-y and non-food bank credit by 15.6 per cent as on May 19, 2023. India’s foreign exchange reserves were placed at US$ 595.1 billion as on June 2, 2023.

·         Going forward, the headline inflation trajectory is likely to be shaped by food price dynamics. Assuming a normal monsoon, CPI inflation is projected at 5.1 per cent for 2023-24, with Q1 at 4.6 per cent, Q2 at 5.2 per cent, Q3 at 5.4 per cent and Q4 at 5.2 per cent. The risks are evenly balanced.

·         The government’s thrust on capital expenditure, moderation in commodity prices and robust credit growth are expected to nurture investment activity. Weak external demand, geoeconomic fragmentation, and protracted geopolitical tensions, however, pose risks to the outlook. Taking all these factors into consideration, real GDP growth for 2023-24 is projected at 6.5 per cent with Q1 at 8.0 per cent, Q2 at 6.5 per cent, Q3 at 6.0 per cent, and Q4 at 5.7 per cent, with risks evenly balanced.

·         The next meeting of the MPC is scheduled during August 8-10, 2023.

Credit Growth Remains Strong in April 2023, Industry Subdued (CARE Ratings)

Gross bank credit offtake rose by a robust 15.9% year on year (y-o-y) in April 2023 due to continued strong growth in services and personal loans especially driven by growth in lending to Non-Banking Financial Companies (NBFCs), vehicle loans, and unsecured personal loans1 segments.

·         Credit growth for the services segment was robust at 21.8% y-o-y in April 2023 as compared with 11.2% a year-ago period due to growth in NBFCs, retail trade and other services.

·         Personal loan growth accelerated by 19.4% y-o-y in April 2023 from 14.4% a year-ago period, driven by credit cards, housing, vehicle loans and other loans.

·         Industry credit offtake growth moderated at 7.0% (y-o-y) from 8.0% over a year ago, registering a lower growth compared to personal loans and services. Infrastructure witnessed a marginal rise of 1.7% due to growth in roads and others, however, power, ports, airports, and telecom dropped in the month.

·         Agriculture and allied activities rose by 16.7% in April 2023 vs. 10.6% in April 2022.

FY23 Corporate performance insights (Bank of Baroda)

FY23 Growth in sales was steady though lower than last year. Growth in net profits has slowed down for both the aggregate sample as well as the one which excludes BFSI companies. The difference from the past is that growth in net profit margin is positive indicating some recovery.

Table 1 reveals that growth in sales has slowed down from 21% in Q4-FY22 to 12% in Q4-FY23 for the sample of 2096 companies while that in net profits has moved from 26.1% to 17.3% during this period. There has been improvement in net profit margin in both the years.

Table 2 excludes BFSI companies. Here the performance is relatively muted with sales growth of 8.8% and net profit of 7.5%. The higher base effect as well as dilution of pent up demand in some sectors contributed to this slower growth. The net profit margin however has been falling over the last two years of this quarter though the dip in Q4-FY23 has been very marginal.

A significant observation here is that the interest cover ratio for the sample of 1797 companies came down to 5.82 from 6.45 last year after witnessing an improvement in FY22. This was a result of both lower growth in PBIT as well as higher interest costs due to the lending rates increasing in the banking system. PBIT had grown by just 4.8% this quarter compared with 9.4% last year. However, interest costs increased sharply by 16.3% compared with 4.7% in Q4-FY22.

 - The industries which grew at a higher rate than the average were: banks, insurance and Finance in the BFSI sector. Services received a boost from the pent up demand which got reflected in hospitality, diamonds and jewellery, logistics, IT, retail, and trading. Within manufacturing auto did well on the consumer oriented front while construction material, power and industrial gases performed positively on the industrial front.

- Low growth was witnessed in case of textiles, alcohol, plastic products, mining, gas transmission and iron and steel.

- Food based products and health care had maintained their sales growth at the average level which was also the case with paper.

- Industries like electricals, FMCG, chemicals, infra, capital goods, media, telecom, realty, consumer durables registered single digit growth. Price pressures did come in the way of demand; and rural demand was less robust than expected across some of these industries.

Real estate (Kotak Securities)

Cautious road, treading between vacancies and occupancies: Commercial real estate in top Indian cities is facing headwinds despite improved quarterly leasing. Existing vacancies are primarily in SEZ areas, which may be hard to fill up until the regulatory amendment comes through, while current occupancies have a large presence of IT companies, among which Cognizant is taking the lead to rationalize the need for office space among key Indian cities. In that backdrop, FY2024E may not be able to repeat the strong showing of FY2023, which saw leased area increase to 524 mn sq. ft, with record absorption (78 mn sq. ft/39 mn sq. ft of gross/net leasing). Yields have improved due to price correction, but visibility on FY2024E remains lackluster.

Healthy gross and net absorption, new supply falls further: All-India commercial real estate (aggregate of top 7 cities) had an outstanding stock of 615 mn sq. ft (+7% yoy, +1% qoq) as of March 2023, with gross absorption a tad lower on a sequential basis but still healthy at 18.4 mn sq. ft (+1% yoy, -8% qoq). Net absorption during the quarter stood at 9.4 mn sq. ft (+14% yoy, -1% qoq), while new supply in 4QFY23 slowed further to 7.6 mn sq. ft (-38% yoy, -11% qoq). Consequently, vacancy declined 2% qoq to 90.6 mn sq. ft, with vacancy improving to 14.7% (15.4% in 4QFY22 and 15.2% in 3QFY23).

Among cities, Gurgaon led the improvement in occupancy, with gross and net absorption of 2.3 mn sq. ft and 1.1 mn sq. ft, respectively, and nil new supply during the quarter. Accordingly, vacancy declined to 26.1% in 4QFY23 (27.4% in 4QFY22 and 27.3% in 3QFY23). Mumbai also saw an improvement, with net absorption and new supply at 1.3 mn sq. ft and 1.2 mn sq. ft, respectively, and vacancy at 15% (17.7% in 4QFY22 and 15.3% in 3QFY23). Bengaluru saw a slight increase in vacancy to 6.9% (from 6.8% in 3QFY23, 4QFY22 at 7.5%), as net absorption of 2.2 mn sq. ft lagged new supply of 2.6 mn sq. ft. Hyderabad, Pune, Noida and Chennai saw net absorption of 1.7 mn sq. ft, 1.8 mn sq. ft, 0.7 mn sq. ft and 0.6 mn sq. ft, against new supply of 1.1 mn sq. ft, 1.2 mn sq. ft, 1.5 mn sq. ft and nil, respectively. Blended rentals saw sequential moderation (+4% yoy, -6% qoq)—most large cities saw a correction. Total leased area rose 8% yoy and 2% qoq to 524 mn sq. ft as of March 2023.

SEZ clarification key for further occupancy improvement: Commercial asset owners suggest that the demand scenario is robust, with rising occupancy across geographies. Clarity on the DESH bill and allowing floor-by-floor de-notification are key, although any occupancy improvement would take at least 2-3 quarters post the amendment as the non-SEZ occupancy is already at 93-94% levels for most asset owners. Accordingly, an improvement in overall occupancy should only be very gradual hereon. Exhibit 4 highlights the break-up of vacancy between SEZ and non-SEZ areas. In our view, even if the regulatory amendment comes through in 1HFY24, the process of de-notification and leasing of vacant spaces will only close by end-FY2024.

Leasing trends: GCC expansion to offset some weakness in IT but overall improvement may take time Cognizant has announced its plans to vacate 11 mn sq. ft of space in tier-1 and metro cities (with subsequent plan to acquire space in smaller cities), we would watch out for commentary from other large employers (tech, BFSI) for cues. For now, asset owners see the Cognizant announcement as a part of regular business, stating that the vacancy should happen only gradually, while also offering asset owners the opportunity to mark-to-market the rents in some of their old contracts. Data on non-software service exports corroborates the strength in GCC growth in India—assets owners remain optimistic that GCC strength will help absorb any release of office spaces by technology companies, and also help improve overall rent rates for their portfolios. IT companies have seen a slowdown in hiring over the past few quarters, with 4QFY23 seeing a decline in headcount across tier-1 IT companies in comparison to expansion in every quarter since the beginning of the pandemic. Global Capability Centers (GCCs) continue to expand in India, especially in Bengaluru.

Electrodes: Demand Headwinds Likely to Impact Near-Term Pricing (Jefferies)

Weak demand (global & domestic) impacted Electrode pricing and utilization in Q4FY23. Exports are ~70%/50% of HEG/GRIL's sales. We foresee demand headwinds to persist in FY24e, and lower our est for electrode ASPs and utilizations (now to ~65%) for both cos. We cut

FY25-26e EBITDA by 8-16%, but expect higher impact in FY24e. Beyond the near-term headwinds, decarbonization stays a medium-term tailwind; 7mnMT EAF capacity has commissioned in US in last 12M. Buy.

Demand Headwinds Persist: In FY23, global crude steel production dipped by 4-5%YoY amid weaker offtake across many regions. But Indian production grew by 5-6%YoY. Domestic demand accounts for ~50% of GRIL's sales mix, but is lower at ~30% for HEG. Weak global offtake impacted HEG's capacity utilization to 75% in FY23 (-1,200bps YoY). Electrode pricing has also declined by ~3%QoQ in Q4. Industry channel inventory is est to be higher-than-normal currently. We foresee demand headwinds to continue in FY24e as well, and hence cut our estimates for electrode ASPs and utilizations for both companies. HEG's 20K MT extra capacity is likely to commission in Jun'23. While we expect HEG's FY24e utilization to decline to 65% (75% in FY23), absolute volumes could grow by +10%YoY due to its higher total capacity now at 100K MT. We cut GRIL/HEG's capacity utilization by -10%/-14% resp in FY24e to 65-66%, but pencil in revival to 75-80% in FY25e led by a recovery in demand.

EBITDA Pressure: Softer demand offtake (lower volumes) and weaker pricing are likely to impact EBITDA margins of both GRIL & HEG. Resultant impact on EBITDA is est to be higher in FY24e than in FY25-26e. Needle Coke (NC) prices are also softening, but the drop in electrode pricing is likely to be higher than NC in FY24e. We cut electrode cos' FY25-26e EBITDA by 8-16%, while FY24e cut is est to be sharper owing to steeper cut in utilizations and pricing. We est FY24e EBITDA margin at +12%/16% for GRIL/HEG resp.

Decarbonization - A Medium-Term Tailwind: Exports account for ~70% of HEG's sales mix, and ~50% for GRIL. While global EAF steel production is 45-50% ex-China, China is still lower at low-double-digit (2x since 2016). US is ~70% EAF production now, and now accounts for ~10% of HEG's sales mix, having risen 2-3x in the last 4 years. New EAF capacity of ~7mnMT has already commissioned in last 12M, and incremental ~17mn MT of EAF is expected to commission in the USA in the medium-term.

India Pharma: Moats intact, volume recovery key (Axis Capital)

Promising trends: strong pricing, growth in chronic/ new-age drugs IPM grew a steady 9% YoY in FY23 (3-year CAGR at ~9%) after 2% /15% Covid-affected growth in FY21/22. Despite various disruptions (GST, NLEM*, Covid, etc.), IPM has seen steady ~10% growth over the past 10 years led by volume (despite the impact of trade generics, Jan Aushadhi, etc.), price hikes (higher inflation) and new launches (following the expiry of patent exclusivities). Key trends:

Price growth is likely to remain high, at 5-6%, due to the 12.1% hike taken in NLEM products (~14% of IPM) and ~5% hike on the rest in the wake of inflation.

Volume growth in Chronic has started to improve after a dip in demand due to Covid fatalities in the co-morbid cohort. Within Acute, a strong flu season saw the recent recovery in anti-Infectives/ Respiratory, which had moderated post the Covid spike.

Growth in Respiratory is led by price and volume, while growth in Cardiac is largely led by price hikes with tepid volume growth.

Prescription growth in traditional anti-Diabetes is slowing, while new-age molecules like DPP4, SGLT2 and combinations are picking up, increasingly prescribed by general practitioners (GPs) in addition to conventional prescriptions by specialists.

India formulations– superior business model: India sales (20-100% of company sales) remain the key earnings contributor for most pharma companies due to steady growth visibility, higher return ratios, and superior FCF. Notably, branded generic models allow for price increases (to help offset rising costs). We expect domestic-focused companies to outperform IPM growth given:

Focus on building mega brands (sales of Rs 500 mn to Rs 2+ bn)

Expanding field force – to increase coverage in newer markets (tier 2/3 cities)

M&As (strong balance sheet) that can fill gaps and augment existing therapies

Risk from pricing control/ generics – limited impact: NPPA’s price control list, last revised in Dec’22, has partially impacted Q4FY23 growth –which pharma companies expect to counter with increased volumes (given strong brands) and price hikes (from Apr’23). Pricing policies are unlikely to impact sales beyond a point given competitive pricing by most. Trade generics, private label and Jan Aushadhi are seeing a brisk ramp-up in sales, however, this model faces challenges in supply, SKU shortages and concerns regarding quality from patients and doctors. More inside: market shares, companies (not covered, not listed as well)

Market share across therapies, companies, brands, bonus contribution, NLEM, Jan Aushadhi, trade generic coverage, etc.

Snapshots on major pharma companies highlighting (a) 5-year trends in volume, price and new introductions, (b) market share/other trends across key therapies/brands, (c) trends in Chronic vs. Acute mix, etc.

Specialty chemicals: Growth continues to moderate (nuvama institutional equities)

Overall, sales for the sector grew a mere 6% YoY/3% QoQ, driving EBITDA growth also at 6% while maintaining EBITDA margins at 22%. Demand for specialty chemicals catering to agrochem innovators such as PI and SRF remains strong while players catering to generic molecules witness weakness as supplies from China increases. Fluorpolymers demand remained strong; however, refrigerant gas prices have started softening. Overall, trends in specialty chemical demand remains weak as softening RM prices are leading to inventory liquidation across the channel.

Multiple headwinds hamper FY24 growth: Refrigerant gas players such as SRF, Gujarat Fluoro gave cautious commentary on softening refrigerant gas prices; however, specialty chemicals catering to agrochem (PI, SRF, Anupam Rasayan) remains confident of ~20%-plus growth. Players with higher share of commodity – Aarti, Deepak Nitrate and Jubilant Ingrevia continue to maintain weak commentary as demand from end-user industry remains sluggish.

However, they expect a pickup in H2FY24. FMCG-led players like Galaxy and Fine Organics are seeing strong demand in domestic market; however, facing challenges in Europe and US given the inflationary scenario and inventory liquidation.

Outlook and valuation: Growth moderation factored in: Most players set a cautious tone on the back of: i) inventory liquidation impacting demand; ii) slowdown in markets like Europe and US; and iii) price correction in categories like refrigerant gases. However, the industry is witnessing strong domestic demand and growing enquiries in exports as global players continue to look for alternatives to China and increasing outsourcing to reduce cost.

We acknowledge headwinds in FY24 – factored in to our estimates. We expect growth driven by sustained capex, FY25 to witness growth revival while current valuations (sector average at 23x Y25E P/E) limit downside.